Cancer Biologynpj Precision OncologyPeer-reviewed
Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer
Esther P. B. Rodman, Michael J. Emch, Xiaonan Hou…·John R. Hawse
This study identifies lestaurtinib as a potent inhibitor of ovarian cancer, effective against resistant models, by targeting JAK/STAT signaling and synergizing with standard therapies.
8 citations